Novozymes A/S
Novozymes A/S (NVZMY) Financial Performance & Income Statement Overview
Analyze Novozymes A/S (NVZMY) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Novozymes A/S (NVZMY) Income Statement & Financial Overview
Review Novozymes A/S NVZMY income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $1.08B | $2.002B | $6.83B | $6.83B |
| Cost of Revenue | $483.30M | $959.30M | $3.97B | $3.97B |
| Gross Profit | $594.30M | $1.04B | $2.86B | $2.86B |
| Gross Profit Ratio | $0.55 | $0.52 | $0.42 | $0.42 |
| R&D Expenses | $107.30M | $218.70M | $725.39M | $725.43M |
| SG&A Expenses | $212.30M | $406.00M | $1.34B | $1.34B |
| Operating Expenses | $328.80M | $607.00M | $2.36B | $2.36B |
| Total Costs & Expenses | $812.10M | $1.57B | $6.33B | $6.33B |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $0.00 | $0.00 | $292.31M | $292.25M |
| EBITDA | $275.70M | $435.50M | $1.13B | $1.13B |
| EBITDA Ratio | $0.26 | $0.22 | $0.16 | $0.16 |
| Operating Income | $265.50M | $435.50M | $503.49M | $503.51M |
| Operating Income Ratio | $0.25 | $0.22 | $0.07 | $0.07 |
| Other Income/Expenses (Net) | -$20.80M | -$108.40M | -$167.83M | -$167.84M |
| Income Before Tax | $244.70M | $327.10M | $335.66M | $335.67M |
| Income Before Tax Ratio | $0.23 | $0.16 | $0.05 | $0.05 |
| Income Tax Expense | $58.70M | $85.20M | $97.34M | $97.35M |
| Net Income | $186.00M | $241.90M | $238.32M | $238.33M |
| Net Income Ratio | $0.17 | $0.12 | $0.03 | $0.03 |
| EPS | $0.40 | $0.53 | $0.86 | $0.86 |
| Diluted EPS | $0.40 | $0.53 | $0.86 | $0.86 |
| Weighted Avg Shares Outstanding | $465.00M | $456.42M | $277.90M | $277.90M |
| Weighted Avg Shares Outstanding (Diluted) | $465.00M | $456.42M | $277.90M | $277.90M |
Over the last four quarters, Novozymes A/S achieved steady financial progress, growing revenue from $6.83B in Q1 2024 to $1.08B in Q1 2025. Gross profit stayed firm with margins at 55% in Q1 2025 versus 42% in Q1 2024. Operating income totaled $265.50M in Q1 2025, maintaining a 25% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at $275.70M. Net income dropped to $186.00M, with EPS at $0.40. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan